HOYA
For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high quality, high performing eyeglass lenses, HOYA continuously aims to bring the best possible vision care solutions to Eye Care Professionals and their patients around the world. The company supplies lenses in 110 countries with a network of over 17,000 employees and 43 laboratories around the globe.
HOYA sponsored articles.
HOYA myopia management products
Myopia management products listed by Myopia Profile have been specifically designed for myopia control or myopia management in children, and have some form of regulatory approval or marking for this form of use. They also have randomized controlled trial research data supporting their efficacy, unless otherwise noted. It is up to the individual eye care practitioner to be aware of regulatory requirements for prescribing in their country of practice, and also be aware that not all products are available in all countries.
MiYOSMART iQ
MiYOSMART iQ represents the latest evolution of MiYOSMART spectacle lenses with revolutionary Defocus Incorporated Multiple Segments (D.I.M.S.) technology which is supported by over 90 scientific publications. Building on the DIMS technology, MiYOSMART iQ features a new DIMS Triple Enhanced Design (TED) with three enhancements that drive greater myopia control effectiveness in children.
Defocus segments are positioned closer to the centre of the lens to maintain more consistent stimulation of the near-peripheral retina, the region most sensitive to myopic defocus.1 Each segment provides increased defocus power (from +3.50 D to +4.50 D) to strengthen the defocus signal. Additional defocus segments extend the treatment zone coverage within the peripheral visual field, ensuring consistent stimulus even when lenses are fitted to larger spectacle frames.2
- Swiatczak B, Scholl HPN, Schaeffel F. Retinal ‘sweet spot’ for myopia treatment. Sci Rep 2024; 14: 26773.
- Smith Iii EL, Arumugam B, Hung L-F, et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Res 2020; 177: 32–40.
MiYOSMART
The MiYOSMART spectacle lens can be considered as a first-line treatment for simultaneous myopic correction and myopia control, with a two-year randomized controlled trial showing robust efficacy and acceptance in children. Data for up to six years of wear in children has been published, as well as eight-year data. It can be considered as one of the best available myopia control spectacle lens designs, being superior to progressive addition and bifocal lenses.
HOYA resources
Summary of all MiYOSMART studies
Learn more about the MiYOSMART lens as an innovative and evidence-based option for myopia management, with links to the 2-year and 3-year published studies and 6-year data. Further studies on adaptation, visual function, optics and even combination with atropine via this link.
Myopia Continuing Education
HOYA proudly presents a continuing education platform for ophthalmologists and optometrists in affiliation with recognized and independent world organizations such as the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) and the International Myopia Institute (IMI). These interdisciplinary educational programs are presented in collaboration with leading experts in myopia covering all topics related to myopia in children, the management and treatment thereof, and future consequences of myopia.